IN Therapeutics, Daewoong Pharmaceutical's new drug development arm, signed a major technology export contract worth 750 billion won with U.S.-based Niroda Therapeutics for its NaV1.7-targeting non-opioid painkiller candidate Aneratrigin.

Celltrion has secured a positive CHMP opinion for its SteQeyma ustekinumab biosimilar autoinjector, expanding administration options and strengthening its immunology and biosimilar portfolio in the European market.

Antengene Corporation has received approval from Malaysia's National Pharmaceutical Regulatory Agency for a supplemental New Drug Application expanding XPOVIO indications to include adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least two prior therapies.[1]

CleanGo Innovations’ subsidiary Kubera Black Technology announces plans to acquire Italian specialty pharma company Freia Farmaceutici Srl, aiming to expand its European footprint and globalize Freia’s gynecology, gastroenterology, and pneumology portfolio.

Zuellig Pharma has expanded its regional partnership with Lundbeck to strengthen commercialisation and market access for neuro-psychiatric medicines across key Asian markets.

Grifols has obtained European Medicines Agency approval for the entire plasma-derived medicines value chain of Grifols Egypt, creating a new EMA-compliant manufacturing and supply platform that can serve European markets and strengthen regional plasma sourcing and fractionation capacity.

China's innovative drug sector achieved a historic breakthrough in 2025 with over $100 billion in out-licensing deals, including massive partnerships with Pfizer, GSK, and Takeda, signaling its rise as a global pharma innovator.[1]

Hansa Biopharma has announced a strategic reorganisation of its European and international organisation to sharpen market access, commercial focus, and operational efficiency across its rare disease portfolio.

ProPharma has inaugurated a new office in Hyderabad, India, to expand its pharmaceutical consulting, regulatory, and outsourcing support for Asia-Pacific drug developers and manufacturers.

The European Medicines Agency has published a revised EU guideline on stability testing for post‑approval variations, raising and clarifying CMC data expectations for marketing authorisation holders operating in Europe.